<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lapadula D</submitter><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIH</funding><funding>NIGMS NIH HHS</funding><pagination>963-973</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6445713</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(4)</volume><pubmed_abstract>Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gα&lt;sub>q&lt;/sub> and Gα&lt;sub>11&lt;/sub>, are observed in approximately 93% of all uveal melanomas. Although therapeutic intervention of downstream Gα&lt;sub>q/11&lt;/sub> targets has been unsuccessful in treating uveal melanoma, we have found that the Gα&lt;sub>q/11&lt;/sub> inhibitor, FR900359 (FR), effectively inhibits oncogenic Gα&lt;sub>q/11&lt;/sub> signaling in uveal melanoma cells expressing either mutant Gα&lt;sub>q&lt;/sub> or Gα&lt;sub>11&lt;/sub>. Inhibition of oncogenic Gα&lt;sub>q/11&lt;/sub> by FR results in cell-cycle arrest and induction of apoptosis. Furthermore, colony formation is prevented by FR treatment of uveal melanoma cells </pubmed_abstract><journal>Molecular cancer research : MCR</journal><pubmed_title>Effects of Oncogenic Gα&lt;sub>q&lt;/sub> and Gα&lt;sub>11&lt;/sub> Inhibition by FR900359 in Uveal Melanoma.</pubmed_title><pmcid>PMC6445713</pmcid><funding_grant_id>P30CA056036</funding_grant_id><funding_grant_id>R01 CA218024</funding_grant_id><funding_grant_id>R01 GM088242</funding_grant_id><funding_grant_id>R01 GM056444</funding_grant_id><funding_grant_id>R03 CA202316</funding_grant_id><funding_grant_id>P30 CA056036</funding_grant_id><funding_grant_id>P01 HL114471</funding_grant_id><funding_grant_id>R01 GM56444</funding_grant_id><funding_grant_id>R01 CA109182</funding_grant_id><funding_grant_id>F31 CA225064</funding_grant_id><funding_grant_id>F31 CA224803</funding_grant_id><pubmed_authors>McGrath D</pubmed_authors><pubmed_authors>Benovic JL</pubmed_authors><pubmed_authors>Randolph CE</pubmed_authors><pubmed_authors>Zhou N</pubmed_authors><pubmed_authors>Farias E</pubmed_authors><pubmed_authors>Tall GG</pubmed_authors><pubmed_authors>Aplin AE</pubmed_authors><pubmed_authors>Wedegaertner PB</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Aguirre-Ghiso J</pubmed_authors><pubmed_authors>Terai M</pubmed_authors><pubmed_authors>Sato T</pubmed_authors><pubmed_authors>Lapadula D</pubmed_authors><pubmed_authors>Wu S</pubmed_authors><pubmed_authors>Purwin TJ</pubmed_authors><pubmed_authors>Charpentier TH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of Oncogenic Gα&lt;sub>q&lt;/sub> and Gα&lt;sub>11&lt;/sub> Inhibition by FR900359 in Uveal Melanoma.</name><description>Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gα&lt;sub>q&lt;/sub> and Gα&lt;sub>11&lt;/sub>, are observed in approximately 93% of all uveal melanomas. Although therapeutic intervention of downstream Gα&lt;sub>q/11&lt;/sub> targets has been unsuccessful in treating uveal melanoma, we have found that the Gα&lt;sub>q/11&lt;/sub> inhibitor, FR900359 (FR), effectively inhibits oncogenic Gα&lt;sub>q/11&lt;/sub> signaling in uveal melanoma cells expressing either mutant Gα&lt;sub>q&lt;/sub> or Gα&lt;sub>11&lt;/sub>. Inhibition of oncogenic Gα&lt;sub>q/11&lt;/sub> by FR results in cell-cycle arrest and induction of apoptosis. Furthermore, colony formation is prevented by FR treatment of uveal melanoma cells </description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Apr</publication><modification>2026-03-15T21:01:52.747Z</modification><creation>2025-08-13T03:06:17.71Z</creation></dates><accession>S-EPMC6445713</accession><cross_references><pubmed>30567972</pubmed><doi>10.1158/1541-7786.mcr-18-0574</doi><doi>10.1158/1541-7786.MCR-18-0574</doi></cross_references></HashMap>